Romero-Zoghbi SE, Krumina E, López-Campos F, Couñago F. Current and future perspectives in the management and treatment of colorectal cancer. World J Clin Oncol 2025; 16(2): 100807 [DOI: 10.5306/wjco.v16.i2.100807]
Corresponding Author of This Article
Felipe Couñago, MD, MS, PhD, Chief Doctor, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, Calle de Joaquín Costa, 28, Madrid 28002, Spain. felipe.counago@genesiscare.es
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Feb 24, 2025; 16(2): 100807 Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.100807
Current and future perspectives in the management and treatment of colorectal cancer
Sigfredo E Romero-Zoghbi, Evita Krumina, Fernando López-Campos, Felipe Couñago
Sigfredo E Romero-Zoghbi, Department of Radiation Oncology, GenesisCare Talavera de la Reina, Toledo 45600, Spain
Evita Krumina, Department of Radiation Oncology, GenesisCare Guadalajara, Guadalajara 19004, Spain
Fernando López-Campos, Department of Radiation Oncology, Hospital Universitario Ramón Y Cajal, Madrid 28034, Spain
Fernando López-Campos, Department of Radiation Oncology, GenesisCare-Hospital Universitario Vithas Madrid La Milagrosa, Madrid 28010, Spain
Felipe Couñago, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, Madrid 28002, Spain
Co-first authors: Sigfredo E Romero-Zoghbi and Evita Krumina.
Author contributions: Romero-Zoghbi SE, Krumina E, and Couñago F designed the overall concept and outline of the manuscript; Romero-Zoghbi SE, Lopez-Campos F, and Couñago F contributed to the intellectual discussion and design of the manuscript; Romero-Zoghbi S, Krumina E, Lopez-Campos F, and Couñago F contributed to the writing and editing of the manuscript, and review of literature.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Felipe Couñago, MD, MS, PhD, Chief Doctor, Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, Calle de Joaquín Costa, 28, Madrid 28002, Spain. felipe.counago@genesiscare.es
Received: August 26, 2024 Revised: September 30, 2024 Accepted: October 23, 2024 Published online: February 24, 2025 Processing time: 106 Days and 15.3 Hours
Abstract
In this editorial, we reviewed the article by Fadlallah et al that was recently published in the World Journal of Clinical Oncology. The article provided a comprehensive and in-depth view of the management and treatment of colorectal cancer (CRC), one of the leading causes of cancer-related morbidity and mortality worldwide. The article analyzed the therapeutic modalities and their sequencing, focusing on total neoadjuvant therapy for locally advanced rectal cancer. It highlighted the role of immunotherapy in tumors with high microsatellite instability or deficient mismatch repair, addressing recent advances that have improved prognosis and therapeutic response in localized and metastatic CRC. Innovations in surgical techniques, advanced radiotherapy, and systemic agents targeting specific mutational profiles are also discussed, reflecting on how they revolutionized clinical management. Circulating tumor DNA has emerged as a promising tool for detecting minimal residual disease, prognosis, and therapeutic monitoring, solidifying its role in precision oncology. This review emphasized the importance of technological and therapeutic advancements in improving clinical outcomes and personalizing CRC treatment.
Core Tip: The management of colorectal cancer remains a challenge, but recent advances in total neoadjuvant therapy for advanced rectal cancer and the growing role of immunotherapy in tumors with high microsatellite instability or deficient mismatch repair are transforming the landscape. Modern treatments include new surgical techniques, advanced radiotherapy, and therapies targeting specific mutational profiles. Additionally, circulating tumor DNA is emerging as a crucial tool in precision oncology, improving prognosis and personalizing clinical care.
